SDAI (SGX:5TI) incorporated a wholly owned subsidiary in China, named Beijing Blue Code Biotechnology, a filing with the Singapore Exchange said on Thursday.
The principal activities of the subsidiary include technical consulting and development services, natural science research and development, general sales and retail and e-commerce.
The incorporation was funded through internal resources of the group.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.